Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12617000083392
Ethics application status
Approved
Date submitted
22/12/2016
Date registered
16/01/2017
Date last updated
16/01/2017
Type of registration
Prospectively registered

Titles & IDs
Public title
Pilot study evaluating the efficacy and safety of second generation supraglottic airway devices in adult surgical patients.
Scientific title
Efficacy and safety of second generation supraglottic airway devices in adult surgical patients: a prospective pilot study.
Secondary ID [1] 290803 0
Nil known
Universal Trial Number (UTN)
U1111-1191-1618
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Malpositioned airway device 301452 0
Condition category
Condition code
Anaesthesiology 301173 301173 0 0
Anaesthetics

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The following interventions placed by the consultant anaesthetist, the supraglottic airway devices the LMA-Supreme 'Registered Trademark', LMA-Protector 'Registered Trademark' and i-gel 'Registered Trademark' devices inserted with blind or video-guided methods will be sequentially allocated to each study participant for use as airway management during anaesthesia. Blind or video-guided insertion will be at the clinical discretion of the treating anaesthetist based on skills and preference. Maximum of three attempts will be allowed for each intervention insertion, at which time standard care device is used. Anatomical details will be recorded during insertion for each device using both the blind and video-guided insertion methods. Postoperative incidence of sore throat, dysphagia and dysphonia will also be assessed. Characteristics of each of these supraglottic airway devices (SADs), also termed laryngeal mask airways (LMAs), are as follows:

The LMA-Supreme 'Registered Trademark' (The Laryngeal Mask Company, Le Rocher, Victoria, Mahe,Seychelles) combines features of earlier devices, such as the LMA-ProSeal 'Registered Trademark' (high oropharyngeal seal cuff, gastric access and bite block – to facilitate ventilation, airway protection and airway obstruction, respectively), the LMA-Fastrach 'Registered Trademark' (fixed curve tube and guiding handle – to facilitate insertion and fixation) and the LMA-Unique 'Registered Trademark' (single use – prevention of disease transmission). Furthermore, the LMA-Supreme 'Registered Trademark' incorporates additional features: the anatomically shaped airway tube incorporates a drain tube within its lumen to separate the ventilation and digestive tracts; an elongated cuff at the distal drainage orifice and a 10 degree slant to fit better in the oesophageal tube; an oval-shaped tube to match better the shape of the mouth and to reduce rotation in the pharynx; a strengthened inner cuff to prevent airway obstruction from infolding; and epiglottic fins to prevent airway obstruction from epiglottic downfolding.

The LMA-Protector 'Registered Trademark' (Teleflex Medical, Athlone, Westmead, Ireland) is a later single-use CE-marked and TGA (Therapeutic Goods Administration, Australia) approved laryngeal mask that has similar features to the LMA-Supreme 'Registered Trademark', but has similarities to the LMA-Classic 'Registered Trademark' and LMA-ProSeal 'Registered Trademark', as this device is made entirely from medical-grade silicone. This makes it more flexible and potentially less traumatic than the rigid LMA-Supreme 'Registered Trademark' which is made of polyvinyl chloride. The LMA-Protector 'Registered Trademark' provides access to, and functional separation of the ventilation and digestive tracts. The anatomically shaped airway tube is elliptical in cross-section and ends distally at the laryngeal mask, with the cuff is designed to conform to the contours of the hypopharynx. The LMA-Protector 'Registered Trademark' contains two drainage channels, which emerge as separate ports proximally and enter a chamber, located behind the cuff bowl, which is a new feature. The chamber communicates distally with the upper oesophageal sphincter. Removal of gastric fluid through the upper oesophageal sphincter can be realized by attaching a suction tube to the male suction port or by insertion of a gastric tube through the female drainage port to the stomach.

The i-gel 'Registered Trademark' is an innovative second generation SAD, designed to create a non-inflatable, anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures while avoiding compression trauma. The shape, softness and contours accurately mirror the perilaryngeal anatomy, requiring no cuff inflation.
Intervention code [1] 296720 0
Treatment: Devices
Comparator / control treatment
LMA-Classic 'Registered Trademark' with a blind insertion technique will be the control. The LMA-Classic 'Registered Trademark' (The Laryngeal Mask Company, Le Rocher, Victoria, Mahe, Seychelles) was the original LMA released into the market, and as a first generation device is versatile and re-usable. It is made with soft, silicone and aperture bars, designed to prevent blockage of the airway by the epiglottis. As the standard care device, a maximum of three insertion attempts are allowed.
Control group
Active

Outcomes
Primary outcome [1] 300593 0
The oropharyngeal leak pressure (OPLP) which is a measure of patency of the supraglottic airway will be assessed using a cuff pressure manometer.
Timepoint [1] 300593 0
After successful insertion.
Secondary outcome [1] 330364 0
Incidence of different malpositions of the supraglottic airways observed with the videolaryngoscope.
Timepoint [1] 330364 0
After supraglottic airway insertion.
Secondary outcome [2] 330365 0
Intracuff pressures measured with a manometer.
Timepoint [2] 330365 0
On insertion.
Secondary outcome [3] 330366 0
Capnography assessed by measurement of PaCO2 and waveform interpretation.
Timepoint [3] 330366 0
After insertion.
Secondary outcome [4] 330367 0
Incidence of air leak, assessed by the presence of audible escaping air.
Timepoint [4] 330367 0
After insertion.
Secondary outcome [5] 330368 0
Incidence of airway obstruction assessed by low pulse oximetry readings of SpO2.
Timepoint [5] 330368 0
After insertion.
Secondary outcome [6] 330724 0
Sore throat assessed from patients' telephone feedback using a 10 point Visual Analogue Scale.
Timepoint [6] 330724 0
Postoperatively on day one following surgery.
Secondary outcome [7] 330725 0
Dysphonia assessed from patients' telephone feedback using a 10 point Visual Analogue Scale.
Timepoint [7] 330725 0
Postoperatively on day one following surgery.
Secondary outcome [8] 330726 0
Dysphagia assessed from patients' telephone feedback using a 10 point Visual Analogue Scale.
Timepoint [8] 330726 0
Postoperatively on day one following surgery.

Eligibility
Key inclusion criteria
Patients aged > 18 years;
Planned general anaesthesia;
ASA (American Society of Anesthesiologists) Score 1-3;
Informed written consent.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Requiring endotracheal intubation with a high risk of aspiration;
Pregnancy;
Surgery requiring non-supine positioning;
Head and neck surgery;
Potentially difficult airway.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Descriptive statistics will be used in the form of frequency (percent) for categorical variables, mean (standard deviation) for parametric continuous variables and median (interquartile range) for non-parametric variables to describe the sample and characteristics across groups. Groups will be analysed as intention-to-treat. A two-way ANOVA will be used to assess the differences across treatment groups. Test will be declared statistically significant at a<0.05. Predictive Analytics Software (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0 Armonk. NY:IBM Corp.) will be used for analysis.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
1/02/2017
Actual
Date of last participant enrolment
Anticipated
1/07/2017
Actual
Date of last data collection
Anticipated
1/07/2017
Actual
Sample size
Target
160
Accrual to date
Final

Funding & Sponsors
Funding source category [1] 295229 0
Hospital
Name [1] 295229 0
Royal Brisbane and Women's Hospital
Country [1] 295229 0
Australia
Primary sponsor type
Hospital
Name
Royal Brisbane and Womens Hospital
Address
Butterfield Street, Herston. Queensland. 4029.
Country
Australia
Secondary sponsor category [1] 294057 0
University
Name [1] 294057 0
The University of Queensland.
Address [1] 294057 0
St Lucia. Queensland. Australia. 4072.
Country [1] 294057 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 296571 0
Royal Brisbane and Women's Hospital Human Research Ethics Committee
Ethics committee address [1] 296571 0
Ethics committee country [1] 296571 0
Australia
Date submitted for ethics approval [1] 296571 0
30/11/2016
Approval date [1] 296571 0
16/12/2016
Ethics approval number [1] 296571 0
HREC/16/QRBW/547

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 71334 0
Prof Andre Van Zundert
Address 71334 0
Royal Brisbane and Women's Hospital,
Butterfield Street,
Herston. Qld. 4029
Country 71334 0
Australia
Phone 71334 0
+617 3646 5673
Fax 71334 0
Email 71334 0
[email protected]
Contact person for public queries
Name 71335 0
Andre Van Zundert
Address 71335 0
Royal Brisbane and Women's Hospital,
Butterfield Street,
Herston. Qld. 4029
Country 71335 0
Australia
Phone 71335 0
+617 3646 5673
Fax 71335 0
Email 71335 0
[email protected]
Contact person for scientific queries
Name 71336 0
Andre Van Zundert
Address 71336 0
Royal Brisbane and Women's Hospital,
Butterfield Street,
Herston. Qld. 4029
Country 71336 0
Australia
Phone 71336 0
+617 3646 5673
Fax 71336 0
Email 71336 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.